Precision Medicine has the potential to harness the vast advances in technology, genetics and biomedical research to understand the roots of disease, develop targeted therapies, and ultimately provide predictive, preventive and precise care to patients. Hospital and healthcare systems are moving toward the routine sequencing of every patient’s genome in the quest for “precision medicine,” a course for prevention and treatment based on the special and unique characteristics of the patient’s genes.
Efforts into this approach are already being implemented in some areas of medicine, such as cancer research, and in pilot projects in leading academic medical centers.
Precision medicine has the potential to deliver some of the most significant changes on the healthcare horizon; improving diagnosis, treatment and patient prognosis. The arrival of precision medicine is imminent. Ensuring its successful and appropriate adoption will be vital to hospitals and healthcare systems and the patients they treat. As well as improved outcomes for patients, it also has the potential to bring significant efficiency, savings, transforming health and saving lives and money.
From techniques that enable doctors to test tumor samples for hundreds of mutations to activating the immune system to fight cancer and using drugs intended for one indication to successfully treat another, truly individualized success stories are an exciting feature of modern medicine. Could the information revealed by sequencing your genome be the secret weapon against deadly diseases? What tools can turn genomic data into crucial medical information on a large scale? Realizing the Potential of Precision Medicine, October 9-11, 2013 will discuss the advances that have been made, those yet to come, and how every patient can gain access to the most individualized medicine possible.
So much knowledge is available right now in our health records and genetic data. Now we need the tools to access it, so we can make sense of that data and truly provide personal, predictive, precise care to our patients.
~Susan Desmond-Hellmann, MD, MPH, Chancellor of the University of California, San Francisco
The conference is researched, designed and ideally suited for Administrators, CEOs, COOs, Presidents, Vice Presidents, Directors and Health Care Professionals representing Academic Medical Centers, Community Hospitals and Hospital and Health Networks, involved in:
Cancer Genetics, Inc. (CGI) is an emerging leader in DNA-based cancer diagnostics and services some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals as well as biopharma and biotech. Our state-of-the-art reference lab is focused entirely on maintaining clinical excellence and is both CLIA certified and CAP accredited and has licensure from several states including New York State. CGI has established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic and the National Cancer Institute.
Selah Genomics is a clinical diagnostic specialist supporting healthcare providers and the pharmaceutical industry with advanced molecular and genomic diagnostic services. Selah’s services add value to early stage drug development, clinical trials and regulatory processes in the pharmaceutical industry and helps clinicians and healthcare providers treat and monitor patients, thereby improving patient outcomes.
With the Power of Precision, Selah Genomics provides the best in molecular diagnostic testing, assay validation and genomic profiling that all leads to one common goal: to provide better outcomes for patients.
Published either daily or weekly, the Bloomberg BRIEF newsletters pull together the reporting, insight and analysis of senior editorial staff and dedicated economists to help you stay informed and ready for your daily business needs. The 18 newsletter titles offer cutting-edge access to proprietary Bloomberg data and breaking stories that move markets. Take your complimentary trial at www.bloombergbriefs.com
GenomeWeb LLC is an independent, privately-held online and print publisher based in New York. Since 1997, GenomeWeb has served the global community of scientists, technology professionals, and executives who use and develop the latest advanced tools in molecular biology research and molecular diagnostics.
GenomeWeb’s editorial mission is to serve readers with exclusive, in-depth coverage of the technology, institutions, and scientists that make up the worldwide research enterprise of molecular biology. We operate the largest online news organization focused on advanced research tools in genomics, proteomics, and bioinformatics. Our expert editors report and write with precision and clarity.
Healthcare Informatics provides expert insight and in-depth coverage of the latest policy, operational, and technological developments facing the healthcare IT industry, delivering authoritative and timely content through multiple channels to engage and shape the industry. Our core readership remains CIOs and CMIOs, and those who report to them and work with them in the IT and clinical informatics areas in hospitals and health systems. Healthcare Informatics offers a full suite of integrated marketing solutions including print, digital, lead gen, webinars, in-person events and thought leadership, content development, the annual HCI Executive Summit, IT Innovator Awards and the HCI 100.